Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Last week's survey by the British Potato Council revealed that we prefer mash to chips. So is this good news for our health? Nutritionally speaking, both mash and chips are good sources of energy ...

Hyderabad: Calling for a well-defined roadmap to uplift women financially in the State, BRS leader and MLC Kalvakuntla Kavitha on Saturday wanted the State government to present a comprehensive plan ...